natgillin/translations-raw huggingface dataset:
Revlimid is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1).
Zdravilo Revlimid je indicirano za zdravljenje ponovljenega ali na zdravljenje neodzivnega limfoma plaščnih celic pri odraslih bolnikih (glejte poglavji 4.4 in 5.1).
Revlimid is indicated for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Zdravilo Revlimid je indicirano za zdravljenje bolnikov z anemijo, odvisno od transfuzij, zaradi mielodisplastičnega sindroma z majhnim ali srednjim-1 tveganjem, povezano z izolirano citogenetsko nepravilnostjo – delecijo 5q, kadar so druge možnosti zdravljenja nezadostne ali neustrezne.
Revlimid is not recommended for use in children and adolescents under 18 years.
Zdravilo Revlimid ni priporočeno za uporabo pri otrocih in mladostnikih, mlajših od 18 let.
Revlimid is taken in repeated 28-day cycles: the patient takes the medicine once a day for 21 days at around the same time each day, followed by seven days off the medicine.
Zdravilo Revlimid se jemlje v ponavljajočih se 28-dnevnih ciklih: bolnik 21 dni jemlje zdravilo enkrat na dan ob približno istem času, nato ga sedem dni ne jemlje.
Revlimid is taken in treatment cycles, each cycle lasting 28 days (see above “Treatment cycle”).
Zdravilo Revlimid se jemlje v ciklih zdravljenja, ki trajajo po 28 dni (glejte "Cikel zdravljenja" zgoraj).
Revlimid is taken together with an anti-inflammatory medicine called ‘dexamethasone’.
Zdravilo Revlimid se jemlje skupaj s protivnetnim zdravilom, ki se imenuje ‘deksametazon’.
Revlimid is used alone to treat adult patients who have been diagnosed with myelodysplastic syndromes, when all of the following apply:
Zdravilo Revlimid se uporablja samostojno, za zdravljenje odraslih bolnikov z diagnosticiranimi mielodisplastičnimi sindromi, kadar so izpolnjeni vsi naslednji pogoji:
Revlimid is used alone to treat adult patients who have been diagnosed with previously-treated MCL.
Zdravilo Revlimid se uporablja samo za zdravljenje odraslih bolnikov, ki jim postavijo diagnozo predhodno zdravljenega MCL.
Revlimid is used for the treatment of multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma, which are conditions affecting blood cells and bone marrow.
Zdravilo Revlimid se uporablja za zdravljenje multiplega mieloma, mielodisplastičnih sindromov in limfoma plaščnih celic, torej obolenj, ki prizadenejo krvne celice in kostni mozeg.
Revlimid is used in adults for:
Zdravilo Revlimid se uporablja pri odraslih za:
Revlimid may also cause blood clots in the veins (thrombosis).
Zdravilo Revlimid lahko povzroči tudi nastanek krvnih strdkov v venah (trombozo).
Revlimid may reduce the number of white blood cells that fight infection and also the blood cells which help the blood to clot (platelets) which may lead to bleeding disorders e.g. nosebleeds and bruising.
Zdravilo Revlimid lahko zmanjša število levkocitov, ki sodelujejo v boju proti okužbam in tudi število krvnih celic, ki pomagajo pri strjevanju krvi (trombociti), kar lahko povzroči nepravilnosti v kravavitvah, na primer krvavitev iz nosu in modrice.
Revlimid must be given to you by healthcare professionals with experience in treating multiple myeloma or myelodysplastic syndromes and mantle cell lymphoma.
Zdravilo Revlimid vam sme dati samo zdravstveni delavec, ki ima izkušnje z zdravljenjem diseminiranega plazmocitoma ali mielodisplastičnih sindromov in limfoma plaščnih celic.
Revlimid passes into human semen.
Zdravilo Revlimid prehaja v človeško spermo.
Revlimid should not be used in children and adolescents from birth to less than 18 years because of safety concerns (see section 4.4).
Zdravila Revlimid se ne sme uporabljati pri otrocih in mladostnikih od rojstva do starosti 18 let zaradi pomislekov glede varnosti (glejte poglavje 4.4).
Revlimid treatment should be supervised by a physician experienced in the use of anti-cancer therapies (see section 4.4, karyotype).
Zdravljenje z zdravilom Revlimid mora nadzorovati zdravnik z izkušnjami pri zdravljenju raka (glejte poglavje 4.4, kariotip).
Revlimid treatment should be supervised by a physician experienced in the use of anti-cancer therapies.
Zdravljenje z zdravilom Revlimid mora nadzorovati zdravnik z izkušnjami pri zdravljenju raka.
Revlimid was compared with an appropriate medicine chosen by the patients’ doctors, and the main measure of effectiveness was how long it took until the disease got worse.
Zdravilo Revlimid so primerjali z ustreznim zdravilom, ki so ga izbrali njihovi zdravniki, pri čemer je bilo glavno merilo učinkovitosti čas do poslabšanja bolezni.
Revlimid was more effective than placebo at preventing a worsening of previously treated multiple myeloma.
Zdravilo Revlimid je bilo pri preprečevanju poslabšanja stanja predhodno zdravljenega multiplega mieloma učinkovitejše od placeba.
Revlimid works by affecting the body’s immune system and directly attacking the cancer.
Zdravilo Revlimid deluje tako, da vpliva na imunski sistem telesa in neposredno napada raka.
Revolade 12.5 mg film-coated tablets are round, biconvex, white, debossed with ‘GS MZ1’ and ‘12.5’ on one side.
Revolade 12,5 mg filmsko obložene tablete so okrogle, obojestransko izbočene, bele filmsko obložene tablete z oznakama ‘GS MZ1’ in ’12.5’ na eni strani.
Revolade 25 mg film-coated tablets are round, biconvex, white, debossed with ‘GS NX3’ and ‘25’ on one side.
Revolade 25 mg filmsko obložene tablete so okrogle, obojestransko izbočene, bele filmsko obložene tablete z oznakama ‘GS NX3’ in ‘25’ na eni strani.
Revolade 25 mg powder for oral suspension (eltrombopag)
Revolade 25 mg prašek za peroralno suspenzijo (eltrombopag)
Revolade 25 mg powder for oral suspension is available in kits containing 30 sachets; each sachet contains a reddish-brown to yellow powder.
Zdravilo Revolade 25 mg prašek za peroralno suspenzijo je na voljo v kompletih, ki vključujejo 30 vrečic, od katerih vsaka vsebuje rdečerjav do rumen prašek.
Revolade 50 mg film-coated tablets are round, biconvex, brown, debossed with ‘GS UFU’ and ‘50’ on one side.
Revolade 50 mg filmsko obložene tablete so okrogle, obojestransko izbočene, rjave filmsko obložene tablete z oznakama ‘GS UFU’ in ‘50’ na eni strani.
Revolade 75 mg film-coated tablets are round, biconvex, pink, debossed with ‘GS FFS’ and ‘75’ on one side.
Revolade 75 mg filmsko obložene tablete so okrogle, obojestransko izbočene, roza filmsko obložene tablete z oznakama ‘GS FFS’ in ‘75’ na eni strani.
Revolade can also be used to treat low platelet count (thrombocytopenia) in adults with hepatitis C virus (HCV) infections, if they have had problems with side effects while on interferon treatment.
Zdravilo Revolade se lahko uporablja tudi za zdravljenje nizkega števila trombocitov (trombocitopenija) pri odraslih s hepatitisom C (okužba s hepatitis C virusom (HCV)), če so imeli v času zdravljenja z interferoni težave z neželenimi učinki.
Revolade can cause blood test results that may be signs of liver damage - an increase of some liver enzymes, especially bilirubin and alanine / aspartate transaminases.
Zaradi zdravljenja z zdravilom Revolade lahko izvidi krvnih preiskav pokažejo okvaro jeter - lahko se zviša vrednost nekaterih jetrnih encimov v krvi, še posebno bilirubina in alanin-/aspartat- aminotransferaze.
Revolade can make you dizzy and have other side effects that make you less alert.
Pri jemanju zdravila Revolade se lahko pojavi omotica in drugi neželeni učinki zaradi katerih je vaša pozornost lahko zmanjšana.
Revolade is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year and above who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).
Zdravilo Revolade je indicirano za zdravljenje bolnikov s kronično imunsko (idiopatično) trombocitopenično purpuro (ITP), ki so stari 1 leto ali več in se niso odzvali na zdravljenje z drugimi zdravili (npr. kortikosteroidi, imunoglobulini) (glejte poglavji 4.2 in 5.1).
Revolade is medicine that contains the active substance eltrombopag.
Revolade je zdravilo, ki vsebuje zdravilno učinkovino eltrombopag.
Revolade is not recommended for use in children under the age of one year with chronic ITP due to insufficient data on safety and efficacy.
Uporaba zdravila Revolade ni priporočena pri otrocih, ki imajo kronično ITP in so stari manj kot eno leto, na voljo namreč ni dovolj podatkov o varnosti in učinkovitosti.
Revolade is not recommended in women of childbearing potential not using contraception.
Uporaba zdravila Revolade ni priporočljiva pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
Revolade is used for the treatment of:
Zdravilo Revolade se uporablja za zdravljenje:
Revolade is used in patients aged 1 year and above who do not respond to treatment with medicines such as corticosteroids or immunoglobulins; thrombocytopenia in adult patients with chronic (long-term) hepatitis C, a disease of the liver caused by infection with the hepatitis C virus, when the severity of thrombocytopenia is preventing antiviral therapy; acquired severe aplastic anaemia (a disease in which the bone marrow does not make enough blood cells) in adult patients.
Zdravilo Revolade se uporablja pri bolnikih, starih eno leto ali več, ki se ne odzivajo na zdravljenje z zdravili, kot so npr. kortikosteroidi ali imunoglobulini; trombocitopenije pri odraslih bolnikih s kroničnim (dolgotrajnim) hepatitisom C, tj. okvaro jeter, ki jo povzroča okužba z virusom hepatitisa C, kadar zaradi resnosti trombocitopenije protivirusna terapija ni mogoča; pridobljene hude aplastične anemije (bolezni, pri kateri kostni mozeg ne tvori dovolj krvnih celic) pri odraslih bolnikih.
Revolade is used in patients who did not respond to or had received multiple courses of immunosuppressive therapy (medicines that lower the body’s immune defences) and cannot receive haematopoietic (blood) stem cell transplantation.
Zdravilo Revolade se uporablja pri bolnikih, ki se niso zadostno odzvali na imunosupresivno zdravljenje (zdravila, ki zavirajo delovanje naravnega obrambnega sistema telesa) ali so prejeli več ciklov tovrstnega zdravljenja in pri njih ni mogoča presaditev hematopoetskih (krvotvornih) matičnih celic.
Revolade is used to treat a bleeding disorder called immune (idiopathic) thrombocytopenic purpura (ITP) in patients aged 1 year and above who have already taken other medicines (corticosteroids or immunoglobulins), which have not worked.
Zdravilo Revolade uporabljamo za zdravljenje motnje hemostaze, imenovane imunska (idiopatična) trombocitopenična purpura (ITP), pri bolnikih, ki so stari 1 leto ali več in so se pred tem že zdravili z drugimi zdravili (kortikosteroidi ali imunoglobulini), vendar pa je bilo zdravljenje neuspešno.
Revolade may also be used to treat adult patients with low blood counts caused by severe aplastic anaemia (SAA).
Zdravilo Revolade se lahko uporablja tudi pri zdravljenju odraslih bolnikov z zmanjšanim številom krvnih celic, ki ga povzroča huda aplastična anemija.
Revolade powder must be mixed only with water at room temperature.
Prašek zdravila Revolade se sme mešati samo z vodo sobne temperature.
Revolade should be interrupted if platelet counts increase to > 250,000/μl.
Uporabo zdravila Revolade je treba prekiniti, če se število trombocitov poveča na > 250.000/µl.
Revolade was also effective at maintaining adequate levels of platelets in the extension phase of the study.
Zdravilo Revolade je bilo učinkovito tudi za ohranjanje ustreznih ravni levkocitov v podaljšani fazi študije.
Revolade was also more effective than placebo in children with ITP, with around 40% of the patients who took Revolade (25 out of 63) having a platelet count of at least 50,000 per microlitre for at least 6 of 8 weeks between weeks 5 to 12 of the study period, compared with around 3% of those who took placebo (1 out of 29).
Zdravilo Revolade je bilo učinkovitejše od placeba tudi pri otrocih z imunsko trombocitopenično purpuro: pri 40 % (25 od 63) bolnikov, ki so jemali zdravilo Revolade, je bilo število levkocitov najmanj 50 000 na mikroliter najmanj šest od osmih tednov med petim in dvanajstim tednom študije v primerjavi s približno 3 % (eden od 29) tistih, ki so jemali placebo.
REYATAZ 200mg hard capsules
REYATAZ 200 mg trde kapsule
REYATAZ 50 mg oral powder
REYATAZ 50 mg peroralni prašek
REYATAZ 50 mg ORAL POWDER - FOIL SACHET
REYATAZ 50 mg PERORALNI PRAŠEK – FOLIJA VREČICE
REYATAZ capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV- 1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2).
Zdravilo REYATAZ kapsule je ob sočasni uporabi majhnih odmerkov ritonavirja indicirano za zdravljenje s HIV-1 okuženih odraslih in pediatričnih bolnikov, starih 6 let ali več, v kombinaciji z drugimi protiretrovirusnimi zdravili (glejte poglavje 4.2).
REYATAZ given without ritonavir should not be considered in patients treated with a backbone regimen containing tenofovir disoproxil fumarate and with other concomitant medications that reduce atazanavir bioavailability (see section 4.5 In case of withdrawal of ritonavir from the recommended atazanavir boosted regimen) or in case of perceived challenging compliance.
Zdravila REYATAZ brez ritonavirja se ne sme uporabljati pri bolnikih, ki se zdravijo z osnovnim režimom, ki vsebuje dizoproksiltenofovirat fumarat, in z drugimi sočasno uporabljenimi zdravili, ki zmanjšujejo biološko uporabnost atazanavirja (glejte poglavje 4.5 V primeru odtegnitve ritonavirja iz priporočenega režima zdravljenja z okrepitvijo farmakokinetike atazanavirja) ali v primeru pričakovanih težav s sodelovanjem bolnika pri zdravljenju.
REYATAZ once daily dose
Zdravilo REYATAZ, odmerek enkrat na dan
Reyataz oral powder can be used for children aged at
Peroralni prašek zdravila
REYATAZ should be discontinued if severe rash develops.
V primeru pojava hudega kožnega izpuščaja je treba zdravljenje z zdravilom REYATAZ prekiniti.
REYATAZ with food and drink
Zdravilo REYATAZ skupaj s hrano in pijačo
REYATAZ with ritonavir must not be used in patients with moderate to severe hepatic impairment (see sections 4.3, 4.4 and 5.2).
Zdravila REYATAZ se z ritonavirjem ne sme uporabljati pri bolnikih z zmerno do hudo okvaro jeter (glejte poglavja 4.3, 4.4 in 5.2).
REYATAZ/ritonavir has not been
PR intervala.
Reye’s Syndrome is a very rare disease which can be fatal.
Reyev sindrom je zelo redka bolezen, ki je lahko smrtna.
Reye’s syndrome is a very rare disease which can be fatal.
Reyev sindrom je zelo redka bolezen, ki pa je lahko smrtna.
Reykjavikurvegur 78
Reykjavikurvegi 76-78
Reykjavíkurvegi 76-78
Reykjavíkurvegi 76–78
Reykjavíkurvegi 76-78 IS-220 Hafnarfjörður Iceland
Reykjavíkurvegi 76–78 IS-220 Hafnarfjörður Islandija
Reykjavíkurvegur 76 - 78 IS-220 Hafnarfjördur Iceland
Reykjavíkurvegur 76-78 IS-220 Hafnarfjörður Islandija
Reykjavíkurvegur 76-78, IS-220 Hafnarfjörður, Iceland
Reykjavíkurvegur 76-78, IS-220 Hafnarfjörður, Islandija
Reykjavíkurvegur 78, 220 Hafnarfjörður, Iceland
Reykjavíkurvegur 76-78, 220 Hafnarfjörður, Islandija
Reykjavíkurvegur 78, IS-220 Hafnarfjörður Iceland
Reykjavíkurvegur 78 IS-220 Hafnarfjörður Islandija
Reykjavíkurvegur 78, IS-220 Hafnarfjörður Iceland
Reykjavíkurvegur 78, IS-220 Hafnarfjörður Islandija
RF emissions CISPR 11
RF sevanja CISPR 11
Rhabdomyol ysis11
Rabdomioliza11
Rhabdomyolys is11
Rabdomioliza11
Rhabdomyolysis
hipokaliemija
Rhabdomyolysis
Rabdomioliza11
Rhabdomyolysis
urinska inkontinenca, dizurija
Rhabdomyolysis (may affect up to 1 in 100 people) – is breakdown of muscle fibres that can lead to kidney damage.
Rabdomioliza (lahko se pojavi pri največ 1 bolniku od 100 bolnikov) – je razpadanje mišičnih vlaken, ki lahko povzroči okvaro ledvic.
Rhabdomyolysis and blood creatine phosphokinase increased*
rabdomioliza in zvišanje kreatin
Rhabdomyolysis and blood creatine phosphokinase increased*
rabdomioliza in zvišanje kreatin fosfokinaze v krvi
Rhabdomyolysis and severe CPK elevations (> 5 x ULN)
Rabdomioliza in resno povišanje ravni CPK (> 5 x ULN)
Rhabdomyolysis has been uncommonly reported, usually in association with myelotoxicity, severe liver function test abnormalities and/or renal or multiorgan failure.
O rabdomiolizi poročajo redko, običajno v povezavi z mielotoksičnostjo, resnimi nenormalnostmi testov delovanja jeter in/ali odpovedjo ledvic ali več organov.
Rhabdomyolysis Myalgia Stiffness
rabdomioliza mialgija
Rhabdomyolysis Myalgia Stiffness
rabdomioliza mialgija togost
Rhabdomyolysis secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) has been observed rarely in patients with Parkinson’s disease.
Pri bolnikih s Parkinsonovo boleznijo redko opažajo pojav rabdomiolize, ki bi bila posledica hude diskinezije ali malignega nevroleptičnega sindroma (NMS).
Rhabdomyolysis secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) has been observed rarely in patients with Parkinson’s disease.
Redko so opažali rabdomiolizo, ki nastane sekundarno pri težkih diskinezijah ali nevroleptičnem malignem sindromu (NMS) pri bolnikih s Parkinsonovo boleznijo.
Rhabdomyolysis which is the breakdown of muscle fibres that leads to the release of muscle fibre contents (myoglobin) into the bloodstream, seen as muscle pain, being sick, being confused, an abnormal heart rate and rhythm, and possibly dark urine increase in eosinophils (a type of white blood cell).
rabdomioliza, ki je razgradnja mišičnega tkiva, kar povzroči sproščanje vsebine mišičnih vlaken (mioglobina) v krvni obtok in se odraža z bolečinami v mišicah, bruhanjem, zmedenostjo, nenormalnim srčnim utripom, motnjo srčnega ritma, lahko pa tudi s temnim urinom zvišanje števila eozinofilcev (vrsta belih krvnih celic).
Rhabdomyolysis with or without renal failure (see section 4.4),
rabdomioliza z ledvično odpovedjo ali brez nje (glejte poglavje 4.4)
Rhabdomyolysis*
nefrotski sindrom
Rhabdomyolysis,
oslabelost
Rhabdomyolysis, blood creatine phosphokinase increased (see Post – Marketing Data)
rabdomioliza, zvišana koncentracija kreatin fosfokinaze v krvi (glejte “Podatki po pridobitvi dovoljenja za promet”)
rhabdomyolysis, myositis, back pain, muscle twitching, neck pain
rabdomioliza, miozitis, bolečine v hrbtu, trzanje mišic, bolečine v vratu
Rhabdomyolysis, myositis, leg cramps, back pain
rabdomioliza, miozitis, krči v nogah, bolečine v hrbtu
Rhabdomyolysis, myositis, rheumatoid arthritis
rabdomioliza, miozitis, revmatoidni artritis
Rhabdomyolysis, osteonecrosis
rabdomioliza, osteonekroza
rhabdomyolysis, osteonecrosis, muscle inflammation, tendonitis, arthritis
rabdomioliza, osteonekroza, vnetje mišic, tendinitis, artritis
rhabdomyolysis, posture abnormal
rabdomioliza, nenormalna telesna drža
Rhabdomyolysis, Temporomandibular joint syndrome, Fistula, Joint effusion, Pain in jaw, Bone disorder, Musculoskeletal and connective tissue infections and inflammations*, Synovial cyst
rabdiomioliza, sindrom temporomandibularnega sklepa, fistula, izliv v sklep, bolečina v čeljusti, bolezni kosti, okužbe in vnetja mišično-skeletnega sistema, vezivnega tkiva*, sinovialna cista
Rhabdomyolysis, Temporomandibular joint syndrome, Fistula, Joint effusion, Pain in jaw, Bone disorder, Musculoskeletal and connective tissue infections and inflammations*, Synovial cyst
rabdomioliza, sindrom temporomandibularnega sklepa, fistula, izliv v sklep, bolečina v čeljusti, bolezni kosti, okužbe in vnetja mišično-skeletnega sistema in vezivnega tkiva*, sinovialna cista
Rhabdomyolysis/Blood creatine phosphokinase increased
Rabdomioliza/zvišanje kreatin fosfokinaze v krvi
Rhabdomyolysis11
ginekomastija/pov
Rhabdomyolysis11
Rabdomioli za11
Rhabdomyolysis11
Rabdomioliza1
rhabdomyolysis2, muscular weakness2
rabdomioliza2, mišična oslabelost2
Rhabdomyolysis3 **
rabdomioliza3
rhabdomyolysisc, posture abnormalc
rabdomiolizac, nenormalna telesna držac
RHD type 2 virus differs from the classic form of RHD virus since the course of disease is more prolonged, deaths occur later and over a longer period and there are more deaths in young rabbits than in adults.
Virus RHD tipa 2 se razlikuje od klasične oblike virusa RHD, saj je bolezen dolgotrajnejša, pogin se pojavi pozneje in v daljšem časovnem obdobju, smrtnost pa je večja pri mlajših kuncih kot pri odraslih živalih.
Rheumatoid arthritis
Neradiografski aksialni spondiloartrítis
Rheumatoid arthritis
revmatoidnega artritisa
Rheumatoid arthritis
revmatoidnega artritisa,
Rheumatoid arthritis
revmatoidni artritis,
Rheumatoid arthritis (RA)
Revmatoidni artritis (RA)
Rheumatoid arthritis aggravated
poslabšanje revmatoidnega artritisa
Rheumatoid arthritis clinical trials: in controlled rheumatoid arthritis clinical trials (Studies I−IV), elevations of ALT were similar in patients receiving adalimumab or placebo.
Klinična preskušanja pri revmatoidnem artritisu: V kontroliranih kliničnih preskušanjih pri revmatoidnem artritisu (študije I−IV) so bila zvišanja ALT pri bolnikih, ki so dobivali adalimumab, podobna kot pri tistih, ki so dobivali placebo.
Rheumatoid arthritis exacerbation
poslabšanje revmatoidnega artritisa
Rheumatoid arthritis is an inflammatory disease of the joints.
Revmatoidni artirtis je vnetna bolezen sklepov.
Rheumatoid arthritis patients demonstrate a comparable (to healthy subjects) decrease of absolute neutrophil counts following tocilizumab administration (see section 4.8).
Pri bolnikih z revmatoidnim artritisom se je po prejemu tocilizumaba absolutno število nevtrofilcev zmanjšalo primerljivo z zdravimi prostovoljci (glejte poglavje 4.8).
rheumatoid arthritis,
revmatoidni artritis,
Rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis
Revmatoidni artritis, granulomatoza s poliangiitisom in mikroskopski poliangiitis
rheumatoid arthritis, kidney problems,
ladkorna bolezen, revmatoidni artritis, težave z ledvicami,
rheumatoid arthritis, kidney problems,
revmatoidni artritis, težave z ledvicami,
rheumatoid arthritis, psoriasis
revmatoidni artritis, luskavico
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or axial spondyloarthritis without radiographic evidence of ankylosing spondylitis
Revmatoidni artritis, psoriatični artritis, ankilizirajoči spondilitis ali aksialni spondiloartritis brez radiografskega dokaza za ankilozirajoči spondilits
Rheumatoidis arthritis:
Revmatoidni artritis
Rheumocam 1 mg chewable tablets for dogs Rheumocam 2.5 mg chewable tablets for dogs
Rheumocam 1 mg žvečlijive tablete za pse Rheumocam 2,5 mg žvečlijive tablete za pse
Rheumocam 1 mg chewable tablets for dogs Rheumocam 2.5 mg chewable tablets for dogs Meloxicam
Rheumocam 1 mg žvečljive tablete za pse Rheumocam 2,5 mg žvečljive tablete za pse
Rheumocam 15 mg/ml oral suspension for horses Meloxicam
Rheumocam 15 mg/ml peroralna suspenzija za konje
Rheumocam 330 mg granules for horses
Rheumocam 330 mg, zrnca za konje
Rheumocam 330 mg granules for horses.
Rheumocam 330 mg, zrnca za konje.
Rheumocam 330 mg, granules for horses.
Rheumocam 330 mg, zrnca za konje.
Rheumocam 330 mg, granules for horses. meloxicam
Rheumocam 330 mg, zrnca za konje. meloksikam.
Rheumocam 5 mg/ml solution for injection for cats and dogs Meloxicam
Rheumocam 5 mg/ml raztopina za injiciranje za pse in mačke meloksikam
Rheumocam 5 mg/ml Solution for injection for Cattle and Pigs Meloxicam
Rheumocam 5 mg/ml raztopina za injiciranje za govedo in prašiče. meloksikam
Rheumocam chewable tablets are supplied in: PVC/PVDC (250. 60) blister packs with a 20 micron foil.
PVC / PVDC (250. 60) pretisni omoti z 20 mikronsko folijo.
Rheumocam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.
Žvečlijive tablete Rheumocam lahko dajemo s hrano ali brez nje, ker imajo dodano aromo jih večina psov vzame prostovoljno.
Rheumocam contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Zdravilo Rheumocam vsebuje meloksikam, ki spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSPVZ).